+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

ePRO, E-Patient Diaries and eCOA - Global Strategic Business Report

  • PDF Icon

    Report

  • 411 Pages
  • April 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5139503

Global ePRO, E-Patient Diaries and eCOA Market to Reach $4.7 Billion by 2030

The global market for ePRO, E-Patient Diaries and eCOA estimated at US$1.6 Billion in the year 2022, is projected to reach a revised size of US$4.7 Billion by 2030, growing at a CAGR of 14.7% over the analysis period 2022-2030. eClinical Outcome Assessments (eCOAs), one of the segments analyzed in the report, is projected to record a 14.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Epatient Reported Outcomes (epros) segment is estimated at 16.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $561.4 Million, While China is Forecast to Grow at 17.5% CAGR

The ePRO, E-Patient Diaries and eCOA market in the U.S. is estimated at US$561.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$604.6 Million by the year 2030 trailing a CAGR of 17.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.1% and 14% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 13.3% CAGR.

Select Competitors (Total 85 Featured) -

  • Dassault Systemes SE (3DS)
  • Almac Group
  • Clinical Ink, Inc.
  • Criterium, Inc.
  • Dacima Software, Inc.
  • Anju Software
  • ArisGlobal LLC
  • Cogstate Ltd.
  • Cambridge Cognition Ltd.
  • CliniOps Inc.,
  • Castor EDC
  • ClinCapture
  • Clinion
  • Adelphi Group
  • Crucial Data Solutions

What`s New?

  • Special discussions on the global economic climate and market sentiment
  • Coverage on global competitiveness and key competitor percentage market shares
  • Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and research platform
  • Complimentary updates for one year
  • Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Pivotal Role of eCOA, ePRO and Patient Engagement in Transforming Patient Centricity
  • An Introduction to ePRO, E-Patient Diaries and eCOA
  • Influencer Market Insights
  • Global Economic Update
  • World Shifts to an Endemic COVID-19 Strategy With Focus on Multilateral Approach to Managing Future Pandemics
  • From Pandemic to War & Inflation: “Subdued Outlook for 2023 Despite Signs of Easing Inflationary Conditions”
  • Here’s How Inflationary Pressures Affect the Economy
  • Russia-Ukraine War, the Primary Culprit Responsible for the Hardships
  • Although Past Peak in 2023, Efforts to Solve the Inflation Puzzle Should Continue
  • What’s Causing Inflationary Pressures in the Global Market
  • Exhibit 1: Slower Than Anticipated Decline Makes Inflation a Stickier Than Expected Problem to Solve in 2023: Global Inflation Rates (In %) for the Years 2019 through 2024
  • Exhibit 2: Global Economy Faces a Tough Climb Towards Recovery Made Rockier by the War, Persistent Challenges & Slower Decline in Underlying Core Inflation: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024
  • Pandemic Jolt Brings Strategic & Lasting Changes to Healthcare Sector
  • COVID-19 Expedites Healthcare Ecosystem’s Evolution for Better Care & Cost Savings
  • Adoption of Telemedicine Services Accelerates Amidst the Pandemic
  • Exhibit 3: Telemedicine Leads Digital Health Investments Driven by COVID-19: Leading Categories of Digital Health by Funding (In US$ Billion) for the Year 2020
  • Exhibit 4: Telehealth Visits in the US (in Million) for the Years 2019 and 2020
  • Exhibit 5: Global Number of Telemedicine Patients (in Million) for the Years 2016, 2018, 2020, 2023 & 2025
  • Pandemic Impact on eCOA, ePRO Market
  • COVID-19 Outbreak Compels Clinical Trials Industry to Move Towards ePRO
  • eCOA Solutions Help Address Hurdles Due to COVID-19 Pandemic
  • eCOA Playing a Part in Development of COVID-19 Vaccine
  • Global Market Outlook
  • eCOA: The Largest Category
  • ePRO Offers Tremendous Opportunities in Improving Healthcare System
  • Competition
  • Exhibit 6: ePRO, E-Patient Diaries and eCOA - Global Key Competitors Percentage Market Share in 2023 (E)
  • Competitive Market Presence - Strong/Active/Niche for Players Worldwide in 2023 (E)
  • Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Digitalization of Healthcare Services and Rising Importance of Electronic Data Capture Technologies to Fuel Market Growth
  • Exhibit 7: Global Digital Health Market: Annual Revenues in US$ Million by Region/Country for 2020 and 2027
  • Patient Engagement Practices of the Future to be Shaped by Trends of Increased Use of Personal Devices and Passive Data
  • Key Patient Engagement Technology Trends and Innovations
  • eCOA & ePRO: A Powerful Duo Serving Clinical Trials with Electronic Data Collection
  • Rise in Clinical Trials Drives Need for ePRO, ePatient Diaries, and eCOA Solutions
  • Exhibit 8: Number of Registered Clinical Studies (in Thousands) Worldwide for the Period 2010-2023
  • Exhibit 9: Clinical Trials in the US: % Change in Trial Starts by Therapy Area for 2020 Vs 2019
  • Exhibit 10: Percentage Breakdown of Endpoint Adjudication Committees (EAC) Trials by Therapeutic Area: 2023E
  • COVID-19 Pandemic Triggers Technology Adoption in Clinical Trials
  • Exhibit 11: Digital Health Venture Funding in the US (in $ Billion) for the Years 2015-2022
  • Trends in Clinical Trials Space to Influence Market Demand
  • Clinical Trials Increasingly Embraced Technology During COVID-19 Pandemic
  • Shift towards Decentralized/Virtual Clinical Trials to Boost Market Prospects
  • Exhibit 12: Global Virtual Clinical Trials Market Size (in US$ Billion) for the Years 2022, 2024, 2026 and 2028
  • Exhibit 13: Global Virtual Clinical Trials Market by Indication (in %) for 2023E
  • Decentralized Clinical Trials Driving Greater Demand for Patient-Centric Drug Development
  • Role of eCOA & ePRO in Enhancing Data Accuracy of Decentralized Clinical Trials
  • Growing Volumes of Data Generation in Decentralized Trials: A Challenge
  • Adoption of Digital Technologies in Contract Research Organizations Bodes Well for the Market
  • Exhibit 14: Global Contract Research Outsourcing Market Revenues (US$ Million) by Geographic Region/Country for 2020 and 2027
  • Exhibit 15: Pharmaceutical R&D Spending Worldwide (USD Billion): 2015-2025
  • COVID-19 and Implications for Drug Development Regulations & Processes
  • Rise in Telemedicine Services Present Market Opportunities
  • Exhibit 16: Global Telehealth Market (In US$ Million) for Years 2022, 2024, 2026 and 2028
  • Growing Adoption of Mobile Technologies and BYOD Trend in Healthcare Industry Boosts Market Prospects
  • Exhibit 17: Smartphone Adoption Rate as a Percentage of Connections by Region for 2022 and 2030
  • Exhibit 18: Mobile Device Use in Healthcare Settings: % Usage by Type of Mobile Device
  • Electronic Patient Record (ePRO) Solutions Emerge as Ideal Replacements for Paper-Based PRO systems
  • Moving over Paper Pains & Mastering the Art of Real-Time Data Collection with ePRO
  • Delivering Better Data: A Key Benefit of ePRO
  • Factors Ensuring Success of ePRO Implementations
  • ePatient Reported Outcomes (PROs) Gain Importance in Oncology Studies
  • Advances in ePRO Technologies Promise Better Clinical Decision Making in Healthcare Systems
  • Integrating AI into ePRO Improves the Efficiency of ePRO Data Collection and Assessment
  • Data Integrity, Security & Privacy: Key Priorities for ePRO Solutions
  • Electronic Clinical Outcome Assessment Solution (eCOA) Market: Poised for Growth
  • Exhibit 19: Global eCOA Market Breakdown by Delivery Mode (in %) for 2023E
  • Exhibit 20: eCOA Usage by Clinical Trial Phase (in %) for 2021
  • eCOA Grants The Best Route to Improve Data Quality & Patient Experience for Clinical Trials
  • Benefits Offered by eCOA Systems over the Paper-Based Systems in Trials
  • How to Successfully Implement eCOA Systems in Clinical Trials?
  • New Technologies & Approaches with Potential to Augment Statistical Prowess of eCOA
  • Technological Trends Transforming eCOA Solutions Market
  • Future Trends in eCOA Market: A Review
  • eCOA Proves Beneficial in Addressing Clinical Trial Challenges During COVID-19 Pandemic
  • UAT, Challenges and Embedded UAT for eCOAs
  • Benefits of BYOD for eCOAs
  • E-Patient Diaries: Significant Advantages over Paper Diaries to Drive Market
  • Major Benefits of ePatient Diary
  • eCOA & ePRO to Help Mental Health Research Shed the Taboo Status & Move Forward
  • Intriguing Perks of eCOA & ePRO for Mental Health Research
  • Increase in Healthcare Spending to Propel Demand
  • Exhibit 21: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • Increasing Burden of Chronic Diseases and Focus on Drug Development, Therapies and Vaccines Boost Market
  • Exhibit 22: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Exhibit 23: Global Annual Medical Cost of CVD in US$ Billion (2010-2030)
  • Exhibit 24: World Diabetes and Population Statistics (2019, 2030 & 2045)
  • Aging World Population to Drive Market Growth
  • Exhibit 25: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Challenges Facing Companies Implementing eCOA, ePRO & Patient-Centric Clinical Trials
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World ePRO, E-Patient Diaries and eCOA Market Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 3: World 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for eClinical Outcome Assessments (eCOAs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 5: World 8-Year Perspective for eClinical Outcome Assessments (eCOAs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 6: World Recent Past, Current & Future Analysis for ePatient Reported Outcomes (ePROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 7: World 8-Year Perspective for ePatient Reported Outcomes (ePROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Clinician Reported Outcomes (ClinROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 9: World 8-Year Perspective for Clinician Reported Outcomes (ClinROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for ePatient Diaries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 11: World 8-Year Perspective for ePatient Diaries by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 12: World Recent Past, Current & Future Analysis for Performance Outcomes (PerfOs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 13: World 8-Year Perspective for Performance Outcomes (PerfOs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Observer Reported Outcomes (ObsROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 15: World 8-Year Perspective for Observer Reported Outcomes (ObsROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Clinical Trial Sponsors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 17: World 8-Year Perspective for Clinical Trial Sponsors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 18: World Recent Past, Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 19: World 8-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 21: World 8-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 23: World 8-Year Perspective for Academic Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 24: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 25: World 8-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • ePRO, E-Patient Diaries and eCOA Market Presence - Strong/Active/Niche - Key Competitors in the United States for 2023 (E)
  • Market Analytics
  • Table 26: USA Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 27: USA 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
  • Table 28: USA Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 29: USA 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
CANADA
  • Table 30: Canada Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 31: Canada 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
  • Table 32: Canada Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 33: Canada 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
JAPAN
  • Table 34: Japan Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 35: Japan 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
  • Table 36: Japan Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 37: Japan 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
CHINA
  • Table 38: China Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 39: China 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
  • Table 40: China Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 41: China 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
EUROPE
  • ePRO, E-Patient Diaries and eCOA Market Presence - Strong/Active/Niche - Key Competitors in Europe for 2023 (E)
  • Market Analytics
  • Table 42: Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 43: Europe 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
  • Table 44: Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 45: Europe 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
  • Table 46: Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 47: Europe 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
FRANCE
  • Table 48: France Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 49: France 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
  • Table 50: France Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 51: France 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
GERMANY
  • Table 52: Germany Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 53: Germany 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
  • Table 54: Germany Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 55: Germany 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
ITALY
  • Table 56: Italy Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 57: Italy 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
  • Table 58: Italy Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 59: Italy 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
UNITED KINGDOM
  • Table 60: UK Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 61: UK 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
  • Table 62: UK Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 63: UK 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
REST OF EUROPE
  • Table 64: Rest of Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 65: Rest of Europe 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
  • Table 66: Rest of Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 67: Rest of Europe 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
ASIA-PACIFIC
  • Table 68: Asia-Pacific Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 69: Asia-Pacific 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
  • Table 70: Asia-Pacific Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 71: Asia-Pacific 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
REST OF WORLD
  • Table 72: Rest of World Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 73: Rest of World 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2023 & 2030
  • Table 74: Rest of World Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 75: Rest of World 8-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2023 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Dassault Systemes SE (3DS)
  • Almac Group
  • Clinical Ink, Inc.
  • Criterium, Inc.
  • Dacima Software, Inc.
  • Anju Software
  • ArisGlobal LLC
  • Cogstate Ltd.
  • Cambridge Cognition Ltd.
  • CliniOps Inc.
  • Castor EDC
  • ClinCapture
  • Clinion
  • Adelphi Group
  • Crucial Data Solutions

Table Information